Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.
Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe new screenshot shows the same Study Details page (NCT04452214) with no additions or deletions to core content; any differences seem to be minor formatting/layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check18 days agoChange DetectedAdded a dedicated Locations section listing Colorado, Florida, and Pennsylvania as study sites, and removed the separate per-state headers. The page now shows revision: v3.3.3.SummaryDifference0.5%
- Check26 days agoChange DetectedNo additions or deletions detected on the page; the content remains unchanged.SummaryDifference0.1%
- Check47 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check54 days agoChange DetectedRemoved the government funding status notice and related operating-status links from the page.SummaryDifference0.4%
- Check68 days agoChange DetectedThe changes between the old and new pages are non-significant, with core study information unchanged and only minor UI or formatting adjustments observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.